Cite
HARVARD Citation
Sharp, A. et al. (n.d.). PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL. HemaSphere. pp. 1970-1971. [Online].